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Summary 
1. Effects of novel nitric oxide-releasing nonsteroidal anti-inflammatory compounds (NO-
NSAIDs) on induction of nitric oxide (NO) synthase by bacterial lipopolysaccharide (LPS) were 
examined in a cultured murine macrophage cell line J774.  
 
2. LPS-induced nitrite production was markedly attenuated by the nitroxybutylester derivatives of 
flurbiprofen (FNBE), aspirin, ketoprofen, naproxen, diclofenac and ketorolac, with each 
compound reducing accumulated nitrite levels by >40% at the maximum concentrations (100 μg 
ml-1) used.    
 
3.  Further examination revealed that nitrite production was inhibited in a concentration-
dependent (1-100 μg ml-1) manner by FNBE which at 100 μg ml-1 decreased LPS-stimulated 
levels by 63.3 ± 8.6% (n=7). The parent compound flurbiprofen was relatively ineffective over 
the same concentration range, inhibiting nitrite accumulation by 24 ± 0.9 % (n=3) at the 
maximum concentration used (100 μg ml-1). 
 
4. FNBE reduced LPS-induced nitrite production when added to cells up to 4 h after LPS. 
Thereafter, FNBE caused very little or no reduction in nitrite levels. Furthermore NO-NSAIDs 
(100 μg ml-1) did not inhibit the metabolism of L-[3H]arginine to citrulline by NO synthase 
isolated from LPS-activated macrophages. 
 
5. Western blot analysis demonstrated that NO synthase expression was markedly attenuated 
following co-incubation of J774 cell with LPS (1 μg ml-1; 24 h) and FNBE (100 μg/ml; 24 h). 
Thus taken together, these findings indicate that NO-NSAIDs inhibit induction of NO synthase 
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without directly affecting enzyme activity. 
 
6. In conclusion our results indicate that NO-NSAIDs can inhibit the inducible L-arginine-NO 
pathway, and are capable of suppressing NO synthesis by inhibiting expression of NO synthase. 
The clinical implications of these findings remain to be established. 
 
 
Key Words: Macrophage; Inflammation; Nitric oxide; Bacterial lipopolysaccharide; 
Nonsteriodal anti-inflammatory drugs; Inducible nitric oxide synthase. 
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INTRODUCTION 
Nonsteroidal anti-inflammatory compounds (NSAIDs) are amongst the most widely used 
drugs, proving beneficial in preventing several of the deleterious effects associated with the 
pathophysiology of inflammation. The application of these agents is however generally limited by 
their significant untoward effects on the gastrointestinal tract, due mainly to suppression of 
prostaglandin synthesis and the subsequent reduction in vascular perfusion within the gastric 
mucosa (Roth, 1988; Allison et al., 1992, Wallace & Granger, 1992).   
In view of the fact that nitric oxide (NO) increases blood flow to the gastric mucosa 
(MacNaughton et al., 1989; Lippe & Holzer, 1992; Tepperman & Whittle, 1992) we proposed 
that incorporating a NO-releasing moiety into conventional NSAIDs may attenuate their cytotoxic 
effects. This hypothesis has now been tested using nitroxybutylester derivatives (NO-NSAIDs) of 
several orthodox NSAIDs including flurbiprofen and aspirin. When applied in vivo some of these 
novel compounds have been show to retain the potent anti-inflammatory properties of the parent 
drug but more importantly they possess markedly reduced ulcerogenic effects (Wallace et al., 
1994a; 1994b; 1994c). This gastrointestinal-sparing effect of the NO-NSAIDs is presumably due 
to the liberation of NO following metabolism. In this regard we have, in preliminary studies, 
demonstrated that flurbiprofen-nitroxybutylester (FNBE) raises cGMP levels in human cultured 
umbilical vein endothelial cells (Baydoun et al., 1995) and when applied in vivo elevates plasma 
nitrite levels in rats (Wallace et al., 1994b).   
Since both exogenous and endogenous NO have been shown to inhibit induction of NO 
synthase (Park et al., 1994; Mariotto et al., 1995a) and to block the expression of inducible cyclo-
oxygenase (Swierkosz et al., 1995) we have investigated whether selected NO-NSAIDs regulate 
induction of NO synthase and thus NO synthesis in LPS-activated J774 macrophages. A 
preliminary account of this work has been presented in abstract form (Cirino et al., 1995). 
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METHODS 
Cell culture   
The murine macrophage cell line J774 was maintained in continuous culture in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 4.4% NaHCO3, penicillin (100 units ml-1) 
and streptomycin (100 μg ml-1), 2 mM glutamine and 10% foetal calf serum. Monolayers of cells 
were routinely harvested by gentle scraping with a Teflon cell-scraper, diluted 1:10 in fresh 
medium and cultured to confluency at 37oC. 
 
Analysis of nitrite production by LPS-activated J774 cells 
Prior to each experiment, cells were harvested by gentle scraping and plated at a seeding 
density of 105 cells per well in 96-well microtiter plates. Confluent monolayers of cells were 
incubated for 24 h with either DMEM or DMEM containing Eschericia Coli lipopolysaccharide 
(LPS; 1 μg ml-1) alone or in combination with nitroxybutylester derivatives (100 μg ml-1) of 
flurbiprofen (FNBE), aspirin, ketoprofen, naproxen, diclofenac and ketorolac. FNBE was selected 
as the representative compound from this group and investigated further by examining its 
concentration-dependent (1-100 μg ml-1) effect on nitrite production. The parent compound 
flurbiprofen (1-100 μg ml-1) was also investigated. In another series of experiments, FNBE (100 
μg ml-1) was added to wells at various time points after exposure of cells to LPS (1 μg ml-1). To 
determine whether FNBE (100 μg ml-1) itself generated detectable quantities of nitrite, cells were 
incubated with this compound in the absence of LPS. Nitrite production was assayed after 24 h by 
measuring the accumulation levels in the culture medium using the Griess reaction (Green et al, 
1982), as described previously (Baydoun et al., 1993).  
 
Western blot analysis 
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  Confluent monolayers of J774 cells in 24-well culture plates (5 x 105 cells per well) were 
incubated for 24 h with either fresh DMEM or DMEM containing LPS (1 μg ml-1) alone or in 
combination with FNBE (100 μg ml-1), dexamethasone (1 μM) or cycloheximide (0.5 μM). 
Incubations were terminated by rapid aspiration of the cell supernatant followed by washing with 
ice-cold phosphate buffered saline (7.3 g l-1 NaCl, 0.0027 g l-1 KCl, 0.02 g l-1 Na2HPO4, 0.0015 g 
l-1 KHPO4, pH 7.4) containing 200 μM Na+ orthovanadate. Cells were lysed in buffer containing 
63.5 mM Tris-HCl (pH 6.8), 10% glycerol, 2% SDS, 5% ß-mercaptoethanol, 1mM Na+ 
orthovanadate, 1 mM 4-(2-aminoethyl)-benzenesufonylfluoride (AEBSF) and 50 μg ml-1 
leupeptin. Lysates (20 μg protein per lane) were separated by SDS-PAGE on 8% polyacrylamide 
gel and transferred for 3 h at 0.8 mA cm2 onto 0.2 μm nitrocellulose membrane (Anderman and 
Co., Kingston-upon-Thames, Surrey, U.K.). Membranes were blocked for 2 hours in 100 mM 
NaCl, 10 mM Tris, 0.1% (v/v) Tween-20, pH 7.4 (STT) containing 1% (w/v) BSA and 
subsequently probed overnight with mouse monoclonal anti-iNOS antibody (1/500 dilution in 
STT containing 0.2% (w/v) BSA). Blots were washed with STT (6 x 10 min) and incubated with 
horseradish peroxidase-conjugated rabbit anti-mouse IgG (1/10,000) for 1 hour. Following further 
washing (8 x 10 min) in STT, immunoreactive bands were visualised using ECL detection System 
(Amersham). Protein bands were quantified by scanning densitometry (UVP E.A.S.Y. Plus 
Enhanced Analysis System; Ultra-Violet Products Ltd, Cambridge, UK) and the data expressed as 
a percentage of the value obtained for samples from cells treated with LPS alone. 
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Citrulline assay 
J774 macrophages (9.5 x 106 cells) in 75 cm2 culture flasks were activated with LPS (1 μg 
ml-1) for 24 h and harvested with a cell scraper into 1 ml of homogenization buffer containing 50 
mM Tris-HCl, 320 mM sucrose, 1 mM EDTA, 1 mM dithiothreitol, 10 μg ml-1 leupeptin, 10 μg 
ml-1 soybean trypsin inhibitor and 2 μg ml-1 aprotinin. Cells were lysed by freezing the 
suspension at -70oC and thawing at 37oC three times. The lysate was then centrifuged at 10,000 g 
for 60 min at 4oC. Conversion of L-[3H]arginine to L-[3H]citrulline was determined as described 
by Brown et al. (1992). Briefly, 20 μl of 10,000 g supernatant was added to 100 μl of assay buffer 
consisting of 50 mM KH2PO4, 1 mM MgCl2, 0.2 mM CaCl2, 50 mM valine, 1 mM dithiothreitol, 
100 μM NADPH, 1 mM L-citrulline, 20 μM L-arginine and 0.5 μCi ml-1 L-[3H]arginine 
containing 2.7 x 10-11 moles L-arginine μCi-1. When applied, inhibitors and other compounds 
were dissolved directly in the assay buffer. The reactions were monitored for 20 min at 37oC and 
L-[3H]citrulline separated from arginine by adding 1 ml of a 1:1 suspension of Dowex (AG 50W-
8) in water to each sample. The supernatant was transferred into ß-vials and radioactivity 
measured by liquid scintillation counting. 
 
Cell Viability 
Cell viability under different experimental conditions was determined by assessing 
mitochondrial-dependent reduction of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (MTT) to formazan as described by Mosmann (1983). Briefly, after each experimental 
protocol, cells in 96-well plates were incubated with MTT (0.5 mg ml
-1
) for 4 h at 37oC. An 
equal volume of 10% SDS in 0.01 M HCl was then added to all wells and incubated for a further 
3 h to dissolve the accumulated crystals of formazan.  Absorbance was read at 560 nm using a 
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Multiskan II plate reader (Titertek).  
 
Materials 
NO-NSAIDs were synthesised by NICOX Ltd (London, UK.). Tissue culture reagents 
were purchased from Gibco (Paisley, U.K.). LPS from Escherichia coli (serotype 0111:B4), 
flurbiprofen, cycloheximide, dexamethasone, MTT, NG-nitro-L-arginine methylester, ethylene 
glycol-bis(ß-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA) and Dowex (AG 50W-8) were 
obtained from Sigma (Poole, U.K.). Monoclonal antibody for inducible nitric oxide synthase was 
from Affiniti Research Products Ltd (Nottingham, U.K.). Other chemicals were from Sigma or 
BDH and of the highest analytical grade obtainable.  
 
Statistics 
All values are means ± s.e. mean of measurements in at least three different cell cultures 
with 5 replicates per experiment. Statistical analyses were performed using a multiple means 
comparison test (Harper, 1984) validated by comparison with the Newman-Keuls multiple range 
test in the statistical package SPP (Royston, 1984) with the overall confidence levels set at 99% 
(0.01). 
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RESULTS 
Inhibition of nitrite production by NO-NSAIDs 
Incubation of J774 cells with LPS (1 μg ml-1) stimulated nitric oxide production, elevating 
nitrite levels from a basal value of 0.02 ± 0.003 to 0.75 ± 0.01 nmoles μg protein-1 24 h-1 (n=13). 
This increase in nitrite production was markedly attenuated by all the NO-NSAIDs which at 100 
μg ml-1, decreased nitrite levels by greater than 40% (Fig. 1). Further studies revealed that FNBE 
reduced LPS-induced nitrite production in a concentration-dependent (1-100 μg ml-1) manner, 
with 100 μg ml-1 decreasing accumulated nitrite levels by 63.3 ± 8.6% (n=7; Fig 2). In contrast, 
the parent compound flurbiprofen had no significant effect at lower concentrations (1-30 μg ml-1) 
but reduced nitrite production marginally (24.0 ± 0.9% inhibition) at the maximum concentration 
(100 μg ml-1) used (Fig 2; n=3). None of these compounds significantly affected mitochondrial 
reduction of MTT to formazan (data not shown) suggesting that these NO-NSAIDs are not 
cytotoxic to J774 cells even at the highest concentration used.  
Time course analysis revealed that the inhibition caused by FNBE was critically 
dependent on the time of addition of this compound. As shown in Fig. 3, FNBE significantly 
reduced LPS-induced NO production when added up to 4 h after exposure of J774 cells to LPS. 
Thereafter, FNBE had very little or no effect on nitrite production. Furthermore when incubated 
with cells for 24 h in the absence of LPS, FNBE (100 μg ml-1) failed to elevate accumulated 
nitrite levels (0.027 ± 0.003 nmoles μg protein 24 h-1; n=3) above basal values (0.025 ± 0.002 
nmoles μg protein-1 24 h-1; n=3), suggesting that nitrite released from this compound does not 
contribute to the total amount of detectable nitrite produced by LPS activated J774 macrophages.   
 
Effects of NO-NSAIDs on iNOS activity 
Unstimulated J774 cells had no detectable levels of NOS activity. Following activation 
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with LPS (1 μg ml-1) total NOS activity was significantly elevated (36.7 ± 4.7 pmoles L-
[3H]citrulline μg protein-1 20 min-1; n=3) and was unaffected by removal of calcium from the 
reaction buffer using 1 mM EGTA. Conversion L-[3H]arginine to citrulline was, however, 
markedly attenuated by L-NAME, which at 100 μM inhibited L-[3H]citrulline production by 79.7 
± 5.5% (n=3). In contrast FNBE and all the other NO-NSAIDs failed to inhibit conversion of 
[3H]arginine to [3H]citrulline (Table 1).  
 
Western blot analysis 
To determine whether the inhibitory effect of FNBE was due to the inhibition of iNOS 
expression, Western blot analysis was carried out on whole cell lysates using a monoclonal 
antibody for murine iNOS. In lysates from LPS-activated (1 μg ml-1; 24 h) but not from untreated 
cells the iNOS antibody recognised a protein band which migrated at a molecular weight of ~130 
kDa (Fig 4a). The levels of iNOS protein, determined by scanning densitometry, were markedly 
attenuated in lysates from J774 cells activated with LPS in the presence of the protein synthesis 
inhibitor cycloheximide (0.5 μM), or the glucocorticoid dexamethasone (1 μM). Similarly, FNBE 
(100 μg ml-1) reduced iNOS expression substantially and, although less effective than 
cycloheximide, was comparable to dexamethasone (Figs. 4a and b).    
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DISCUSSION  
This study has examined the effects of novel nitric oxide-releasing nonsteroidal anti-
inflammatory drugs on the inducible L-arginine-nitric oxide pathway using the murine 
macrophage cell line, J774. In these cells synthesis of NO from its precursor L-arginine is 
mediated by the Ca2+/calmodulin-insensitive NO synthase enzyme, which unlike its constitutive 
isoform (for review see Moncada et al., 1991; Sessa, 1994) is only expressed following activation 
with LPS and/or other pro-inflammatory mediators (Hibbs et al., 1987; Marletta et al., 1988; 
Baydoun et al., 1993). Under these conditions, induction of NO synthase is time-dependent, 
requires de novo protein synthesis and can be regulated by glucocorticoids such as 
dexamethasone (Di Rosa et al., 1990; Assreuy & Moncada, 1992; Baydoun et al., 1993) acting 
presumably at the level of gene transcription (Marumo et al., 1993).  
In this study we have identified NO-NSAIDs which inhibit this inducible NO generating 
pathway in J774 cells and our data are consistent with a short report by Mariotto et al. (1995b) 
showing that FNBE inhibits iNOS expression in neutrophils when administered to rats in vivo. 
These effects appear to be specific for the NO-NSAIDs since the conventional parent compound 
was relatively ineffective over the same concentration range. This is in contrast to the effects of 
NO-NSAIDs and NSAIDs on the cyclo-oxygenase (COX) pathway where both groups of 
compounds are virtually equipotent in inhibiting prostaglandin biosynthesis (Wallace et al., 
1994b, Mitchell et al., 1994). Thus there may be differential regulation of NO synthase and COX 
enzymes by NO-NSAIDs.   
With regard to NO synthase, our data demonstrate that the inhibition of nitrite production 
by the NO-NSAIDs is due to inhibition of enzyme expression rather than to a direct effect of 
FNBE on enzyme activity. Thus, co-incubation of J774 cells with LPS and FNBE resulted in a 
marked decrease in both accumulated nitrite levels and in NO synthase protein expression but 
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when added several hours after LPS, FNBE failed to inhibit nitrite production suggesting that 
once induced, the activity of NO synthase cannot be modified by FNBE. This was further 
confirmed by the fact that neither FNBE nor the other NO-NSAIDs examined inhibited 
conversion of L-[3H]arginine to citrulline by NO synthase isolated from LPS activated J774 cells.  
This latter finding is in contrast to those made by Assreuy et al. (1993) demonstrating that S-
nitroso-acetyl-penicillamine and S-nitroso-glutathione, compounds capable of liberating NO, 
directly inhibited the activity of iNOS isolated from J774 cells. The reasons for these differences 
are as yet unclear but may be related to the amounts of NO produced by each compounds in 
solution. Unlike conventional NO donors, NO-NSAIDs do not generate substantial quantities of 
NO in vitro but release rather discrete amounts which are perhaps insufficient to directly inhibit 
iNOS activity once expressed. Indeed the quantities of NO produced by NO-NSAIDs appear to be 
in the low nanomolar range and below the limit of detection by the relatively insensitive Griess 
reaction. These levels are however detectable either directly by chemiluminescence (unpublished 
observations) or indirectly by monitoring changes in cGMP levels following incubation of NO-
NSAIDs with cells (Baydoun et al., 1995).  
Although our data suggest that NO-NSAIDs, or at least FNBE, may be acting at the 
molecular level to inhibit NO synthase induction, the precise mechanism by which this effect is 
mediated still remains to be established. A recent report (Kopp & Ghosh, 1994) has suggested 
that aspirin and sodium salicylate inhibit the activation of nuclear factor kappa B (NF-kB), a 
transcription factor activated by pro-inflammatory mediators (Collart et al., 1990; Schreck et al., 
1992; Grilli et al., 1993) and implicated in the transcription of a variety of genes involved in 
inflammation, including that for NO synthase (Mülsche et al., 1993; Sherman et al., 1993; Xie et 
al., 1993; 1994). Whether NO-NSAIDs exert their effects by inhibiting activation of NF-kB 
remains a critical experiment to be carried out. It is worth noting however that in the study carried 
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out by Kopp and Ghosh (1994), relatively high millimolar concentrations of aspirin or sodium 
salicylate were required to inhibit activation of NF-kB.  
In our study all the NO-NSAIDs examined significantly suppressed nitrite production (> 
40%) at micromolar concentrations, which according to the findings of Kopp & Ghosh (1994) 
would be ineffective in blocking LPS-induced NF-kB activation. Of course it is feasible that NO-
NSAIDs are more potent inhibitors of NF-kB, inhibiting activation of the latter either directly or 
indirectly via the release of NO. In this regard NO has recently been shown to cause inhibition of 
NF-kB activation, exerting its effect by enhancing the expression and preventing the degradation 
of the cytoplasmic NF-kB inhibitor, IkBα (Peng et al., 1995). This mechanism of action could 
account for the difference in potency between NO-releasing NSAIDs and conventional NSAIDs 
observed in our study. Furthermore it would be in agreement with a recent report demonstrating 
that sodium salicylate and aspirin inhibit NO synthase induction in rat alveolar macrophages 
when applied at millimolar but not micromolar concentrations (Aeberhard et al., 1995).  
The inhibition observed at higher concentrations by Aeberhard et al. (1995) was 
associated with a marked increase in lactate dehydrogenase release from cells. Since this is 
normally associated with membrane damage it therefore strongly suggests that the inhibition 
observed may simply be the result of the cytotoxic actions of the relatively high millimolar 
concentrations of NSAIDs used in their study. In our study the maximum concentration of drugs 
used was 100 μg ml-1 corresponding to ~300 μM for NO-NSAIDs or ~500 μM for flurbiprofen. 
These concentrations were not cytotoxic since they did not modify mitochondrial activity 
assessed by monitoring mitochondrial reduction of MTT to formazan.  
In conclusion our data have identified NO-NSAIDs as inhibitors of the inducible L-
arginine-NO pathway in J774 macrophages, exerting their effects presumably by inhibiting the  
expression of iNOS. This novel finding provides an additional mechanism by which the anti-
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inflammatory properties of these compounds could be mediated. Further studies determining 
plasma concentrations of these compounds are however required to clarify whether our 
observations have any clinical relevance particularly in chronic inflammation where the dominant 
inflammatory cells are macrophages and overproduction of NO at the sites of inflammation can 
augment the inflammatory response (Boughton-Smith et al., 1993; McCartney-Francis et al., 
1993; Vane et al., 1994; Weinberg et al.,1994; Salvemini et al., 1995).  
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Figure Legends 
 
Figure 1  Inhibition of LPS-induced nitrite production in J774 macrophages by NO-NSAIDs. 
Cells were incubated for 24 h with LPS (1 μg ml-1) alone (control) and in combination with 100 
μg ml-1 of nitroxybutylester derivatives of either flurbiprofen (FNBE), aspirin (ANBE), 
ketoprofen (KPNBE), naproxen (NNBE), diclofenac (DFNBE) or ketorolac (KRNBE). 
Accumulated nitrite in the culture medium was determined by the Griess reaction. Results are 
expressed as % of the LPS response (control; 0.72 ± 0.01 nmoles nitrite μg protein-1 24 h-1) and 
values are the mean ± s.e. mean of at least 3 independent experiments with 5 replicates in each. 
All values are significantly different from control at p<0.01. 
 
Figure 2  Concentration-dependent inhibition of LPS-induced nitrite production in J774 
macrophages by flurbiprofen-nitroxybutylester or flurbiprofen. Cells were incubated for 24 h with 
LPS (1 μg ml-1) alone (control) and in combination with increasing concentrations (1-100 μg ml-
1) of either FNBE (z-z) or flurbiprofen ({-{). Accumulated nitrite in the culture medium was 
determined by the Griess reaction. Results are expressed as % of the LPS response (0.71 ± 0.01 
nmoles nitrite μg protein-1 24 h-1) and values are the mean ± s.e. mean of at least 3 independent 
experiments with 5 replicates in each. *denotes values significantly different from control at 
P<0.01. 
 
 
 
 
Figure 3  Time-dependent inhibition of LPS-induced nitrite production in J774 macrophages by 
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flurbiprofen-nitroxybutylester. Cells were incubated with LPS (1 μg ml-1) alone (control) and in 
combination with FNBE (100 μg ml-1) added at 0-12 h after LPS. Accumulated nitrite in the 
culture medium was determined 24 h after addition of LPS by the Griess reaction. Results are 
expressed as % of the LPS response (0.74 ± 0.016 nmoles nitrite μg protein-1 24 h-1) and values 
are the mean ± s.e. mean of at least 3 independent experiments with 5 replicates in each.  
*denotes values significantly different from control at P<0.01. 
 
Figure 4  A: Western blot analysis of inducible NO synthase in J774 cells. Lysates (20 μg 
protein) from untreated cells (C) and from cells incubated with LPS (1 μg ml-1; 24 h) alone and in 
combination with either dexamethasone (1 μM; Dex), cycloheximide (0.5 μM; Cyc) or 
flurbiprofen-nitroxybutylester (100 μg ml-1; FNBE) were separated by SDS-PAGE, transferred to 
a nitrocellulose and blotted with a mouse monoclonal anti-iNOS antibody. This blot is 
representative of 3 independent experiments.  B: Relative intensity of iNOS protein bands 
quantitated by scanning densitometry. Data are expressed as a percentage of the maximum value 
obtained for cells treated with LPS alone.  
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Table 1  Effects of NO-NSAIDs on isolated NO synthase activity.  
                                                                                    
 
L-[3H]citrulline 
(pmoles μg protein-1 20 min-1)  
                                                                                    
Control  36.7 ± 4.7 
EGTA   30.2 ± 2.9 
L-NAME    7.4 ± 2.1* 
FNBE   36.5 ± 2.7 
ANBE  37.8 ± 2.5 
KPNBE  42.8 ± 4.5 
NNBE  36.3 ± 2.0 
DFNBE  39.2 ± 2.7 
KRNBE  38.6 ± 3.7 
                                                                                    
 
J774 cells were activated with LPS (1 μg ml-1; 24 h) and NO synthase isolated from freeze-thawed lysates by 
centrifugation. The 10,000 x g supernatent was assayed for enzyme activity in the absence (LPS Control) and 
presence of either EGTA (1 mM), NG-nitro-L-arginine methyl ester (L-NAME; 100 μM) or nitroxybutylester 
derivatives (100 μg ml-1) of flurbiprofen (FNBE), aspirin (ANBE), ketoprofen (KPNBE), naproxen (NNBE), 
diclofenac(DFNBE) or ketorolac (KRNBE). L-[3H]citrulline production is expressed as pmoles L-[3H]citrulline μg 
protein-1 20 min-1). Values are the mean ± s.e. mean of 3 independent experiments with 3  
